<DOC>
	<DOCNO>NCT00069745</DOCNO>
	<brief_summary>PURPOSE : The SPARC trial design compare combination investigational oral cytotoxic drug , satraplatin , prednisone , versus prednisone alone second line chemotherapy patient hormone-refractory prostate cancer ( HRPC ) . TARGET PATIENT POPULATION : The SPARC trial intend patient hormone-refractory prostate cancer ( HRPC ) whose disease progress treatment one chemotherapy regimen . Please refer Eligibility Criteria page key inclusion exclusion criterion . WHAT IS SATRAPLATIN : Satraplatin member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally . Satraplatin also platinum-based drug demonstrate efficacy prostate cancer randomize trial . RATIONALE : There currently approve chemotherapy drug second line treatment hormone-refractory prostate cancer ( HRPC ) . In preliminary randomized trial conduct Europe , combination satraplatin prednisone superior activity compare prednisone alone , treatment HRPC patient previously treat chemotherapy</brief_summary>
	<brief_title>Satraplatin Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>Stage D2 metastatic prostate cancer Progression one prior chemotherapy ECOG Performance status equal / le 2 Life expectancy &gt; 3 month Surgical medical castration Adequate bone marrow , hepatic renal function Informed consent More one prior chemotherapy Prior platinum contain compound Prior malignancy Prior significant RT/radionuclide therapy Major GI surgery GI disease affect absorption Disease contraindication steroid Brain metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Cancer Treatment Protocols</keyword>
	<keyword>Antineoplastic protocol</keyword>
	<keyword>One Prior Cytotoxic Chemotherapy Regimen</keyword>
</DOC>